Feb 2019 - Global Life Science Business Partnering- News & Updates

  1. Glenmark enters into exclusive pact with Grandpharma to sell Ryaltris in China.
  2. Bharat Biotech buys Chiron Behring Vaccines from GSK’s Indian vaccine unit.
  3. Cipla and Wellthy Therapeutics Announce Partnership to Offer Digital Therapeutics for Diabetes and Cardiovascular Diseases.
  4. Accord Healthcare, a UK-based subsidiary of Intas Pharmaceuticals, has been granted the rights to a novel FP-001 program by Foresee Pharmaceutical.
  5. Merck moves to buy Immune Design and its cancer vaccines platform for US$300 Million.
  6. Bayer exercised option to obtain full licensing rights for larotrectinib and BAY 2731954 (LOXO-195).
  7. WuXi AppTec CDMO STA Pharma inks exclusive deal with Swiss biotech BioLingus.
  8. AbbVie, Teneobio ink US$90 Million deal to develop BCMA bispecific for multiple myeloma.
  9. Charles River swoops on early-stage CRO Citoxlab for US$510 Million in cash.
  10. Taiho Pharma, Cullinan Oncology join forces on EGFR drug for lung cancer.
  11. Genentech pays Xencor US$120 Million for rights to IL-15 cancer pipeline.
  12. AbbVie, Voyager add Parkinson’s disease, US$65 Million to ‘vectorized’ antibody pact.

Updates at Aagami: 

  1. New Client win from Israel to organize funding for unique medicine for alcohol poisoning.
  2. Aagami offers special pricing as part of 16th Anniversary Celebrations.


Release Date: 10 February 2019

×
Twitter